<< Return to Blog List

Largest Animal Vaccine Company in China Opens Facility in KC Animal Health Corridor

by McKenna Brown | May 31, 2017

Chinese Animal Vaccine Company Locates in the Corridor

Congratulations to our partners in Manhattan, Kansas, on today's announcement that Jinyu Bio-technology Co., Ltd., the largest animal vaccine company in China, will open a vaccine research lab and office at the new K-State Office Park Phase II building in the KC Animal Health Corridor.

The company will locate in a 2,400-sq.-ft. lab facility which will house three offices and 800 sq. ft. of clean room space. The company is also considering the addition of manufacturing facilities in the future. Due to the KC region’s concentration of animal health research and service providers with global ties, Jinyu chose to expand in the Corridor.

KCADC was proud to partner with the following organizations in attracting Jinyu to the KC region:

  • State of Kansas
  • Kansas Department of Commerce
  • City of Manhattan, Kansas
  • Manhattan, Kansas Area Chamber of Commerce
  • Kansas State University
  • Kansas State University Institute for Commercialization
  • KSU Foundation
  • Kansas State University College of Veterinary Medicine
  • Kansas State University Research Foundation
  • Kansas State University U.S.-China Center for Animal Health
  • KC Animal Health Corridor

Read More

About Jinyu Bio-technology Co., Ltd.
About Jinyu Bio-technology Co., Ltd. Jinyu Bio-technology Co. was founded in 1993 and is the largest animal vaccine company in China. Jinyu has a complete portfolio for animal vaccines, which includes ruminants, swine and poultry. It is the leading manufacturer of FMD vaccines in China. Jinyu is also one of the few Chinese animal health companies whose products meet international standards. The firm was selected as the 2016 Best Company in Asia and Australasia by Animal Pharm. Jinyu exported vaccines to a number of countries such as Mongolia, Bangladesh and Egypt. Jinyu’s average annual sales growth rate has been over 30% since 2012. In the most recent financial year, Jinyu recorded 17% sales growth with a 38% net profit margin.

Jinyu has China's only uniquely designated national animal vaccine engineering lab, BSL-3 lab and animal facilities, where it develops its pipeline of advanced animal vaccines. Jinyu is also currently constructing a new biological science and technology industrial park in Hohhot that is scheduled to open in 2018. The Jinyu International Biotechnology Industrial Park covers an area of 110 acres and has planned a US$363 million investment for phase one to build up an animal vaccine production and R&D base. By recognizing innovations as its core competitiveness and a strong engine for growth, Jinyu visions to lead the China animal health industry by expanding international markets in the next five years.

About the KC Animal Health Corridor
Companies with a business location in the KC Animal Health Corridor account for more than half of the sales generated by the global animal health industry. The Corridor, anchored by Manhattan, Kansas, and Columbia, Missouri, is home to more than 300 animal health companies, representing the largest concentration in the world. For more information, visit

KC by the Numbers

News Releases


KC News